• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.13% Nasdaq Up0.70%

    Rosetta Genomics, Ltd. (ROSG)

    -NasdaqCM
    2.33 Down 0.02(0.85%) Dec 26, 3:57PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Rosetta Genomics, Ltd.
    10 Plaut Street
    Science Park
    Rehovot, 76706
    Israel - Map
    Phone: 972 73 222 0700
    Fax: 972 73 222 0701
    Website: http://www.rosettagenomics.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Medical Laboratories & Research
    Full Time Employees:45

    Business Summary 

    Rosetta Genomics Ltd. develops and commercializes microRNAs based diagnostic tests and therapeutics. MicroRNAs are a group of genes that are produced using instructions encoded in DNA. It offers diagnostic tests, including Rosetta Cancer Origin test, a microRNA-based diagnostic to identify 42 tumor types that include carcinomas, soft tissue tumors, lymphoma, and other malignancies; Rosetta Mesothelioma test to differentiate mesothelioma, a cancer connected to asbestos exposure and other risk factors, from other carcinomas in the lung and pleura; Rosetta Lung Cancer test, a lung cancer classification test for cytology samples; and Rosetta Kidney Cancer test, a microRNA-based kidney tumor classification test for pathology samples. The company also focuses on developing tissue-based microRNA biomarkers for the differential diagnosis of indeterminate thyroid fine needle aspirate samples; blood-based microRNA biomarkers in order to develop a new diagnostic test for early diagnosis and refined risk stratification of patients following myocardial infarction; microRNA-based diagnostic test for the early diagnosis of Alzheimer’s disease; and blood- or urine-based microRNA biomarkers to develop a diagnostic test for chronic kidney rejection. It distributes its products primarily in Australia, Canada, Greece, India, Israel, New Zealand, Qatar, Romania, Saudi Arabia, Singapore, Turkey, and the United Arab Emirates. The company has a collaboration agreement with Clalit Health Services for the development of a non-invasive microRNA-based assay for the diagnosis of chronic allograft dysfunction or chronic rejection, following kidney transplantation; a strategic alliance with Marina Biotech, Inc. to develop microRNA-based diagnostics and therapeutics for rare diseases; and a collaboration agreement with Biocept, Inc. to evaluate microRNAs from circulating tumor cells. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Rosetta Genomics, Ltd.

    Key Executives 
     PayExercised
    Mr. Brian A. Markison , 54
    Chairman, Observer To Board of Directors and Member of Nominating & Corp. Governance Committee
    N/AN/A
    Mr. Kenneth A. Berlin , 50
    Chief Exec. Officer and Pres
    N/AN/A
    Mr. Ron Kalfus CPA, 40
    Chief Financial Officer and Principal Accounting Officer
    N/AN/A
    Dr. Dganit Bar Ph.D., 45
    Chief Scientific Officer
    N/AN/A
    Mr. Oded Biran Adv., 35
    Chief Legal Officer and Sec.
    N/AN/A
    Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.